Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- Drug Wholesalers Suffer 1st Sales Drop since 1997
August 10, 2015
- Sumitomo Dainippon Will Be Able to Cover the Loss of Long-Listed Drug Sales: President
August 10, 2015
- Pharmaceutical Sales Down 2.4% in 1st Half Due to Loss of Patent Protection for Abilify in US: Otsuka Holdings
August 10, 2015
- Sosei’s UK Subsidiary, AZ Partner for Development of Cancer Immunotherapies
August 10, 2015
- ASCO Immunotherapy Roundup - 5: Merck & Co. Discovers New Biomarkers for Keytruda
August 7, 2015
- Sanofi Files NDA for Hypercholesterolemia Treatment Alirocumab in Japan
August 7, 2015
- Pfizer Japan Pays 14.8 Billion Yen to Doctors, Medical Institutions in FY2014 under Transparency Guidelines
August 7, 2015
- Japan Pharma Market Up 7.9% in April-June 2015: IMS
August 6, 2015
- 14-Day Limit on Prescriptions Considered Unnecessary from a Safety Standpoint in the US and Europe: Pfizer Pres. Umeda
August 6, 2015
- 80% Generic Target “Completely Unexpected,” and Makes Stable Growth in Japan Market Difficult: Pfizer Pres.
August 6, 2015
- AZ Japan Sales Up 2% to US$977 Million in 1st Half of 2015
August 6, 2015
- Astellas Transfers Muscle Relaxant Suxamethonium to Maruishi on Oct. 1
August 6, 2015
- Naldemedine Demonstrates Favorable Results in 3 PIII Efficacy Studies for Opioid-Induced Constipation: Shionogi
August 5, 2015
- Santen Transfers Anti-Rheumatic Business to Ayumi Pharmaceutical
August 5, 2015
- GSK Suspends Shipment of Anti-MRSA Agent Bactroban
August 5, 2015
- Daiichi Sankyo to Submit 4 Products for Approval in Japan and Overseas through FY2018
August 4, 2015
- Edoxaban Doing Well in Japan, but Off to a Rocky Start in US: Daiichi Sankyo
August 4, 2015
- Astellas Not Keen on Biosimilars: CFO Masuda
August 4, 2015
- Japan’s 1st Insulin Biosimilar Launched: Eli Lilly Japan, NBI
August 4, 2015
- Fuji Pharma to Obtain Marketing Rights for 3 Imaging Agents from Guerbet Japan
August 4, 2015
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…